Senseonics delivers 60%+ growth, >50% gross margin, but guides major opex ramp
- 2025 revenue grew ~60% to $35.3M, with Q4 up 72% YoY.
- Q4 revenue was $14.3M and beat analyst estimates for the quarter.
- Gross margin exited 2025 above 50%, up from ~25% in 2024.
- Q4 non-GAAP EPS -$0.46 declined 15% YoY versus Q4 2024 and missed expectations.
- U.S. Eversense patient base doubled; new patient starts increased 103% during 2025.
- Active prescribers grew 80% and EON inserter network handled ~25% of insertions.
- 2026 revenue guided to $58–62M, implying 65–76% YoY growth.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.